Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
25 hedge funds and large institutions have $5.64M invested in Oncternal Therapeutics, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 9 closing their positions.
193% more capital invested
Capital invested by funds: $1.93M → $5.64M (+$3.71M)
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
4% more funds holding
Funds holding: 24 → 25 (+1)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Creative Planning
Overland Park,
Kansas
|
+$2.44M |
| 2 |
DY
Dowling & Yahnke
San Diego,
California
|
+$676K |
| 3 |
Millennium Management
New York
|
+$503K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$452K |
| 5 |
UCFA
United Capital Financial Advisors
Irving,
Texas
|
+$391K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of New York Mellon
New York
|
-$113K |
| 2 |
Goldman Sachs
New York
|
-$89K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$73K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$47.4K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$32.7K |
ONCT Hedge Fund Activity: Q3 2019 in Review
25 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2019, worth a combined $5.64M — up 193% from $1.93M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ONCT positions and 9 closed out — a net gain of 1 holder — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Creative Planning, opening a new position worth an estimated $2.44M. The largest seller was Bank of New York Mellon, exiting entirely with an estimated $113K sold.
- 25 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2019, up from 24 in Q2 2019.
- Funds reported $5.64M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2019, up 193% quarter-over-quarter.
- 10 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2019 and 9 closed out, a net change of +1 holder.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2019 was Creative Planning, an estimated $2.44M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2019 was Bank of New York Mellon, an estimated $113K sold.
Based on aggregated 13F filings for Q3 2019.